|
Current therapy of myelodysplastic syndromes.
|
Jul 2013
|
Blood Rev
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes, or are they?
|
Nov 2016
|
Blood Rev
|
myelodysplastic syndromes (MDS)
|
|
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
|
Apr 2019
|
Blood Reviews
|
myelodysplastic syndromes (MDS)
|
|
Current and emerging strategies for management of myelodysplastic syndromes
|
Dec 2020
|
Blood reviews
|
myelodysplastic syndromes (MDS)
|
|
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease
|
Oct 2016
|
Blood Transfus
|
myelodysplastic syndromes (MDS)
|
|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria
|
Dec 2020
|
Blood, cells, molecules & diseases
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
|
Aug 2016
|
BMC Cancer
|
myelodysplastic syndromes (MDS)
|
|
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po
|
May 2016
|
BMC Hematol
|
myelodysplastic syndromes (MDS)
|
|
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
|
Apr 2019
|
BMJ Case Reports
|
myelodysplastic syndromes (MDS)
|
|
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy
|
Sep 2014
|
BMJ Support Palliat Care
|
myelodysplastic syndromes (MDS)
|
